<DOC>
	<DOCNO>NCT00126672</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , sirolimus , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well sirolimus work treat patient angiomyolipoma kidney .</brief_summary>
	<brief_title>Sirolimus Treating Patients With Angiomyolipoma Kidney</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy sirolimus , term objective response rate , patient angiomyolipoma kidney secondary tuberous sclerosis ( TSC ) lymphangioleiomyomatosis ( LAM ) . - Determine toxicity drug patient . Secondary - Determine change TSC lesion ( e.g. , tuber , subependymal giant cell astrocytomas , facial angiofibromas , kidney cyst ) patient TSC treat drug . - Determine change pulmonary disease patient LAM treat drug . OUTLINE : This multicenter study . Patients receive oral sirolimus daily 12 month absence unacceptable toxicity . After completion study treatment , patient follow 6 month 1 year . PROJECTED ACCRUAL : A total 13-35 patient accrue study within 3-30 month .</detailed_description>
	<mesh_term>Angiomyolipoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis angiomyolipoma kidney secondary tuberous sclerosis ( TSC ) lymphangioleiomyomatosis ( LAM ) * Tumor â‰¥ 2 cm MRI NOTE : *Diagnosis LAM chest CT scan No angiomyolipomarelated bleed impend bleed No evidence severe LAM , define dependence continuous oxygen Untreated renal cell carcinoma PATIENT CHARACTERISTICS : Age 18 65 Performance status Not specify Life expectancy Not specify Hematopoietic Hematocrit &gt; 27 % ANC &gt; 1,500 Platelet count &gt; 100,000 Hepatic SGOT SGPT &lt; 2 time normal Bilirubin &lt; 2 time normal Alkaline phosphatase &lt; 2 time normal Renal eGFR 30 high No evidence accelerate renal dysfunction No acute renal failure Cardiovascular No history coronary artery disease Pulmonary See Disease Characteristics Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No unstable seizure , define recent change seizure pattern change antiepileptic drug regimen No active infection PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 30 day since prior investigational agent More 6 month since prior vascular embolization therapy treatment kidney angiomyolipomas No concurrent chronic use diltiazem , ketoconazole , rifampin No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>angiomyolipoma</keyword>
</DOC>